Plandaí Biotechnology, Inc. announced that it will be expanding the previously announced clinical trial involving poultry to also include a Phytofare® catechin-proPheroid® formulation in grain-based pellets. If successful, this new delivery method could open the door for introducing pH2™ catechins, rich in antioxidants and omega 3 and 6 fatty acids as a wellness food supplement, for various livestock animals, such as poultry and bovines, and pets, including hooved animals, dogs, cats and birds. In a previously announced clinical trial, Plandaí completed the initial study with pH2™ catechins formulated in water to determine the efficacy levels in slaughter chicken plasma. Based on these findings, the new investigations will determine the levels of pH2™ catechin absorption through formulation into animal feed. This new approach has the potential to a provide an efficient method of controlling and protecting the clinical dosage of pH2™ catechins to the animal's blood plasma. The first phase of the new 3-phase poultry investigation is scheduled to commence in the second half of June following Ethics committee approval. The collective studies are designed to clinically demonstrate that pH2™ catechins are protected and delivered to the animals' blood plasma with overall benefits relating to improved wellness, reduced mortality levels and the reduction of the commercial growing life-cycle of the slaughter chicken.